In October of this year, the nonprofit organization HealthyWomen, a group that seeks to educate women to make informed choices about their health, hosted its first Biosimilars and Women’s Health Science and Policy Forum. The daylong forum offered expert perspectives on the state of biosimilars in the United States, legislative and regulatory updates, and a look at challenges and opportunities for biosimilars to improve women’s access to treatment. This week on the podcast, we’re speaking with one of the presenters from that meeting, Lisa Kennedy Sheldon, PhD, APRN, AOCNP, FAAN.
In October of this year, the nonprofit organization HealthyWomen, a group that seeks to educate women to make informed choices about their health, hosted its first Biosimilars and Women’s Health Science and Policy Forum. The daylong forum offered expert perspectives on the state of biosimilars in the United States, legislative and regulatory updates, and a look at challenges and opportunities for biosimilars to improve women’s access to treatment. This week on the podcast, we’re speaking with one of the presenters of that meeting, Lisa Kennedy Sheldon, PhD, APRN, AOCNP, FAAN.
Sheldon is the chief clinical officer of the Oncology Nursing Society, where she oversees clinical strategy to support oncology nurses, advanced practice nurses, and researchers. She also practices as an oncology nurse practitioner at St Joseph Hospital in Nashua, New Hampshire.
Learn more about HealthyWomen at their website.
Biosimilars Policy Roundup for March 2023—Podcast Edition
April 2nd 2023On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
How Health Policy Can Impact Adoption for Adalimumab Biosimilars
September 25th 2022In this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, discussed current policy initiatives that could help biosimilar adoption and how the Inflation Reduction Act is expected to influence the adalimumab market.
Not So Different: Kathy Oubre on What Oncology Practices Have Lacked During the Pandemic
October 18th 2020We sat down with Kathy Oubre, chief operating officer at the Pontchartrain Cancer Center, to discuss what practices have had to forgo during the coronavirus disease 2019 (COVID-19) crisis and how biosimilar access has been affected.